Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

16.7%

2 terminated/withdrawn out of 12 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

8%

1 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

3 recruiting1 with results

Enrollment Performance

Analytics

Phase 1
4(36.4%)
N/A
3(27.3%)
Phase 2
3(27.3%)
Phase 4
1(9.1%)
11Total
Phase 1(4)
N/A(3)
Phase 2(3)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (12)

Showing 12 of 12 trials
NCT02600208Phase 2Active Not Recruiting

Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies With Alpha Beta TCell and B Cell Depletion Using the CliniMACS Device

Role: collaborator

NCT04464434Phase 4Completed

Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis

Role: collaborator

NCT07192900Phase 1Recruiting

Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease

Role: collaborator

NCT00959140Not ApplicableActive Not Recruiting

Standardization of CD3+ T Cell Dose for Patients Receiving Allogeneic Peripheral Blood Stem Cell Transplantation From Matched Related Donors

Role: collaborator

NCT01881334Unknown

Expanded Access to T-cell Depleted Haplo-Identical Stem Cells for Patients Receiving Haplo-Identical and Unrelated Cord Blood Transplants

Role: collaborator

NCT05705570Phase 1Recruiting

Clinical Trial Using CAR- T Cells for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies

Role: collaborator

NCT05281809Phase 2Recruiting

Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia

Role: collaborator

NCT05094206Phase 1Terminated

CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies

Role: collaborator

NCT01033617Not ApplicableCompleted

IMPACT-CABG Trial: IMPlantation of Autologous CD133+ sTem Cells in Patients Undergoing CABG

Role: collaborator

NCT00595127Not ApplicableCompleted

Hematopoietic Stem Cell Transplantation for Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using Total Body Irradiation, Cyclophosphamide and Fludarabine

Role: collaborator

NCT01467232Phase 2Completed

IMPACT-CABG Trial: IMPlantation of Autologous CD133+ sTem Cells in Patients Undergoing Coronary Artery Bypass Grafting

Role: collaborator

NCT01721902Phase 1Terminated

Stem Cell Implantation in Patients Undergoing CABG

Role: lead

All 12 trials loaded